Clinical Trials Browser

Phase 2 × Lymphoma, Large B-Cell, Diffuse × TAK-659 × Clear all

NCT03123393 2023-02-08

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Terminated

49 enrolled 12 charts

Lymphoma, Large B-Cell, Diffuse